This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Hematology/ Hematologic Malignancies  • Leukemias/ Lymphomas  • Immunology  • Immunologic Disorders  • Prognosis/ Outcomes  • Ocular/ Adnexal Tumors  • Drug Therapy  • Alert me on articles by topic

Nobuyuki Ohguro, MD; Noriyasu Hashida, MD; Yasuo Tano, MD

Arch Ophthalmol. 2008;126(7):1002-1003.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Most central nervous system (CNS) lymphomas, including primary intraocular lymphoma, are large B-cell neoplasms that express CD20.¹ Although intravenously administered rituximab, which is a chimeric anti-CD20 human monoclonal antibody, contributes to prolonged survival in patients with systemic large B-cell lymphoma, the drug may not affect the prognosis of CNS lymphoma, possibly because the monoclonal antibody does not effectively penetrate the intact blood-brain barrier. Therefore, intravenous rituximab treatment of ocular lesions associated with CNS lymphoma also could not be expected to be beneficial because of the blood-ocular barrier.

Recent studies^2-3 have shown that 1 intravitreous injection of rituximab is safe in rabbit eyes. Kitzmann et al³ also reported that 3 to 4 injections of rituximab did not cause significant ocular toxic effects in patients with primary CNS lymphoma. However, because their patients were all treated with either additional systemic treatment or ocular . . . [Full Text of this Article]

Report of Cases

Case 1

Case 2

Comment

AUTHOR INFORMATION